Share through
St. Jude Research Logo
About Us
Care & Treatment
Research
Training
Get Involved
Ways to Give
St. Jude Research
WHY ST. JUDE
Back
WHY ST. JUDE
Data and Visualization Tools
Shared Resources
Why St.Jude
Translation Innovation
Scientific Milestones
DEPARTMENTS & LABS
Back
DEPARTMENTS & LABS
Departments
View all departments
Labs
View all labs
Clinical Research
View all clinical researchers
CENTERS & INITIATIVES
Back
CENTERS & INITIATIVES
Comprehensive Cancer Center
Pediatric Translational Neuroscience Initiative
Blue Sky
St. Jude Research Collaboratives
Centers & Initiatives
Global Impact on Infectious Disease
Center of Excellence for Data-Driven Discovery
CAREERS
Search
When autocomplete results are available use up and down arrows to review and enter to select. Touch device users, explore by touch or with swipe gestures.
Home
Why St. Jude
Shared resources & core facilities
Technology Licensing
Biologics
Biologics
Amylase or maltose to treat or prevent neurodegeneration (SJ-20-0009)
Anti-GD2-BB-zeta chimeric receptor (SJ-13-0035)
Antibodies to Tim4 for use as an immune enhancer and cancer therapeutic (SJ-18-0006)
Association of neuraminidase regulated exocytosis with cancer metastasis (SJ-11-0012)
B7-H3-CAR 41BB ligand co-stimulation for solid tumors (SJ-19-0014)
CD123 CARs with a CD20 safety switch for treatment of AML (SJ-19-0025)
CD33 CAR (SJ-17-0010)
CD7 CAR placed in CD7neg memory cells (SJ-15-0020)
Chimeric IL13-MyD88 and PDL1-MyD88 receptors (SJ-20-0032)
Chimeric gene and protein generated Optogranules: Light induced stress granules (SJ-18-0010)
DNA methylation profile and biomarkers to identify functional T-cells (SJ-17-0002)
DNMT3a knockout CAR T cells with Antigen Specificity (for solid tumors) (SJ-19-0024)
Development and optimization of a serotype-independent method of adeno-associated virus (AAV) harvest and purification (SJ-16-0036)
Differentiating T-cells (SJ-18-0019)
Erythroid Specific Promoter for Hematopoietic Disorders (SJ-16-0040)
Extradomain-B fibronectin (EDB)-targeted CAR immune cell therapy (SJ-19-0029)
Fibcd1 to treat or prevent muscle wasting (SJ-20-0008)
GMCSF.IL18 chimeric cytokine receptor for solid tumors (SJ-19-0028)
GRP78 targeted adoptive cell therapy for surface GRP78+ (pediatrics and adult) cancer (SJ-19-0050)
Gene Therapy Vector Insulator Elements (SJ-20-0026)
Generation of therapeutic T cell receptors for fibrolamellar cancer (SJ-19-0046)
HMGA2 in gene therapy vectors (SJ-16-0014)
Hybrid compounds to treat gastrointestinal infections (SJ-14-0019/UTA 14-01)
IL13 promoter to express therapeutic genes (SJ-18-0042)
IL35 receptor (SJ-08-0039)
Immune cells with DNMT3A gene modifications (SJ-16-0009)
Improved GD2 Ab for neuroblastoma (SJ-17-0017)
Improvement producing proteins to treat lysosomal storage disorders (SJ-01-0020)
Improving HSC engraftment by inhibiting GASP genes (SJ-16-0029)
Inhibiting Mir-451 to treat Beta-Thalassemia (SJ-20-0030)
Interleukin-35 (IL-35) (SJ-06-0016)
MAGE-A11 inhibitor for cancer (SJ-20-0033)
MRT67307 treatments for enhancing NK cells (SJ-21-0020)
Minimized Liver Specific Promoter to Improve Gene Therapy Vectors (SJ-04-0024)
Modulating Regulatory T Cells By Targeting Foxp3 Enhancers (SJ-22-0010)
Myd88 and CD40 costimulatory domains for chimeric antigen receptors (SJ-18-0021)
Neuropiln 1 (Nrp1) modulation for immune system control (SJ-13-0012)
PDZ CARs (SJ-22-0011)
Predicting T-cell development stage (and therapy success) (SJ-19-0033)
Primer Panel for T cell receptor amplification (SJ-21-0039)
Primer generation of T-Cell Receptor (TCR) sequences for immune response (SJ-19-0017)
Promoter modification to reduce AAV contamination (SJ-19-0003)
Protease Serine 21 (PRSS21) targeted immunotherapies (SJ-18-0043)
REGNASE-1 gene knockout or BATF overexpression for improving T-cells (SJ-19-0027, SJ-20-0007)
RIPK3 fusion protein for cancer and autoimmunity (SJ-12-0036)
Rapid cloning of T cell receptors (SJ-16-0001)
Regulating p53 translation and function (SJ-05-0002)
SJ293TS cell line (SJ-19-0054)
Safety test for gene therapy vectors (SJ-15-0027)
Selecting and modifying CD7 Cells (SJ-20-0012)
Signatures associated with highly functional CAR T cells (SJ-22-0008)
TNC and COL11A1 CARs (SJ-21-0009)
Universal Chimeric Receptor for T-Cell Therapy (SJ-13-0031)
VIPR1 modulators for improving auditory capabilities (SJ-22-0023)
Zip Cytokine Receptor CARs (SJ-22-0002)
cBAF Inhibitors for Improving T Cell Immunotherapy (SJ-22-0015)
miRNAs for treating cerebral ventricle enlargement in schizophrenia patients (SJ-19-0039)
p53 inhibitory oligonucloeotides (SJ-09-0015)
For more information
Contact the
Office of Technology Licensing
:
Phone: (901) 595-2342
Fax: (901) 595-3148
OTL Intellectual Properties Newsletters
More Technologies
Antibodies for basic research
Diagnostics
Drug Discovery Development Tools
Drugs
Other Technologies
Vaccines